Compounds > platinum(ii) 1,2-diaminocyclohexane malonate
Page last updated: 2024-12-08

platinum(ii) 1,2-diaminocyclohexane malonate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

platinum(II) 1,2-diaminocyclohexane malonate: RN given refers to (SP-4-2-(trans))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID148583
SCHEMBL ID2174031
MeSH IDM0057109

Synonyms (11)

Synonym
(sp-4-2-(trans))-(1,2-cyclohexanediamine-n,n')(propanedioato(2-)-o,o')platinum
platinum(ii) 1,2-diaminocyclohexane malonate
malonato-1,2-diaminocyclohexaneplatinum (ii)
platinum (ii), (cyclohexane-1,2-diammine)malonato-
nsc-224,964
platinum, (1,2-cyclohexanediamine-n,n')(propanedioato(2-)-o,o')-, (sp-4-2)-
jm 74
PHM ,
SCHEMBL2174031
DTXSID80966736
platinum(2+) propanedioate--cyclohexane-1,2-diamine (1/1/1)

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Preliminary results have suggested that malonato-platinum presented several pharmacokinetic features in common with DDP."( Clinical pharmacology and pharmacokinetics of cis-platinum and analogs.
Bonnay, M; Gouveia, J; Mathe, G; Ribaud, P, 1981)		0.26
" MP appears to have several pharmacokinetic features in common with cisplatin: rapid binding to protein, a prolonged terminal phase half-life involving primarily bound platinum, and incomplete excretion by the kidney."( Pharmacokinetics of Malonato (1,2 diaminocyclohexane) platinum.
Alcock, N; Burchenal, JH; Kelsen, DP; Mathe, G; Ribaud, P; Young, CW, 1981)		0.26

Dosage Studied

ExcerptRelevanceReference
" Using flameless atomic absorption spectrophotometry, the pharmacokinetics of MP were studied at five dosage levels."( Pharmacokinetics of Malonato (1,2 diaminocyclohexane) platinum.
Alcock, N; Burchenal, JH; Kelsen, DP; Mathe, G; Ribaud, P; Young, CW, 1981)		0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (86.67)18.7374
1990's2 (13.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.51 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.67%)6.00%
Case Studies1 (6.67%)4.05%
Observational0 (0.00%)0.25%
Other13 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amifostine anhydrous
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.		1.9810diamine;
organic thiophosphate		antioxidant;
prodrug;
radiation protective agent
platinum
Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.		2.3520elemental platinum;
nickel group element atom;
platinum group metal atom
fanft
FANFT: A potent nitrofuran derivative tumor initiator. It causes bladder tumors in all animals studied and is mutagenic to many bacteria.		1.9510
1,2-diaminocyclohexyl platinum sulfate
1,2-diaminocyclohexyl platinum sulfate: RN given refers to cpd without isomeric designation		2.6530
carboplatin
[no description available]		1.9710
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		1.9710L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
phosphorus
Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.		1.9810monoatomic phosphorus;
nonmetal atom;
pnictogen		macronutrient
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		03.5630
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.5630
Leukemia L 1210
[description not available]		03.0650
Anaphylactic Reaction
[description not available]		01.9510
Allergy, Drug
[description not available]		01.9510
Dysembryoma
[description not available]		01.9510
Cancer of Testis
[description not available]		01.9510
Anaphylaxis
An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.		01.9510
Drug Hypersensitivity
Immunologically mediated adverse reactions to medicinal substances used legally or illegally.		01.9510
Teratoma
A true neoplasm composed of a number of different types of tissue, none of which is native to the area in which it occurs. It is composed of tissues that are derived from three germinal layers, the endoderm, mesoderm, and ectoderm. They are classified histologically as mature (benign) or immature (malignant). (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1642)		01.9510
Testicular Neoplasms
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.		01.9510
Bladder Cancer
[description not available]		01.9510
Experimental Neoplasms
[description not available]		02.3720
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		01.9510
Carcinoma, Transitional Cell
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.		01.9510
Leucocythaemia
[description not available]		01.9710
Plasma Cell Tumor
[description not available]		01.9710
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		01.9710
Plasmacytoma
Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.		01.9710
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		01.9710